Back to Authors

Abuhalimeh, Batool

A5022283496 | I1316902750

Mayo Clinic

Cleveland Clinic

Citations 1

Treatment Barriers in Portopulmonary Hypertension

Hepatology | August 1, 2018 | Volume: 69 | Issue: 1 | Pages: 431-443

10.1002/hep.30197 | PMID 30063259

Portopulmonary hypertension (PoPH) is a form of pulmonary arterial hypertension (PAH) that can develop as a complication of portal hypertension. Treatment of PoPH includes PAH‐specific therapies, and in certain cases, such therapies are necessary to facilitate a successful liver transplantation. A significant number of barriers may limit the adequate treatment of patients with PoPH and explain the poorer survival of these patients when compared to patients with other types of PAH. Until recently, only one randomized controlled trial has included PoPH patients, and the majority of treatment data have been derived from relatively small observational studies. In the present article, we review some of the barriers in the treatment of patients with PoPH and implications for liver transplantation.